Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 635858, 13 pages
http://dx.doi.org/10.1155/2015/635858
Research Article

Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

1Medical College, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
2The First Affiliated Hospital of Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
3Institute of Biomedicine and Department of Cellular Biology, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
4Hangzhou Iron and Steel Company Worker Hospital, 1 Kangjian Road, Gongye Area, Hangzhou, Zhejiang 310022, China

Received 13 May 2015; Accepted 11 August 2015

Academic Editor: Seong-Gyu Ko

Copyright © 2015 Yanhong Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To evaluate the therapeutic effectiveness and safety of shenqi fuzheng injection (SFI) in the associated chemotherapy of breast cancer. Methods. 1247 subjects were included in this study for meta-analysis with RevMan 5.3. Results. The clinical curative effective rate (OR = 2.03, 95% Cl [1.44, 2.86], ), grades of KPS (OR = 4.11, 95% Cl [2.74, 6.16], ), CD3+ cells (MD = 7.05, 95% Cl [0.45, 13.64], ) and CD4+ cells (MD = 8.60, 95% Cl [2.67, 14.54], ) and CD4/CD8+ cells (MD = 0.35, 95% Cl [0.14, 0.56], ), WBC (OR = 0.30, 95% Cl [0.20, 0.46], ), PLT (OR = 0.36, 95% Cl [0.20, 0.67], ), gastrointestinal reaction (OR = 0.21, 95% Cl [0.14, 0.32], ), and ECG (OR = 0.26, 95% Cl [0.13, 0.51], ) in the experimental group were superior to the control group. While there were no differences between two groups in CD8+ (MD = 0.21, 95% Cl [−2.81, 3.23], ), NK+ (MD = 1.06, 95% Cl [−9.40, 11.53], ), RBC (OR = 0.49, 95% Cl [0.14, 1.74], ), liver function (OR = 0.59, 95% Cl [0.28, 1.24], ), renal function (OR = 0.56, 95% Cl [0.13, 2.45], ), and bone marrow suppression (OR = 0.50, 95% Cl [0.25, 1.01], ). Conclusion. SFI combined with chemotherapy, to some extent, can improve the effectiveness and the security in the treatment of breast cancer; the mechanism may be related to the elevated immunity.